Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: Immunogenicity independent of therapy and no harmful effect in disease

Vaccine

Volumn 31, Issue 1, 2012, Pages 202-206

  Shinjo, Samuel Katsuyuki ^a   de Moraes, Júlio César Bertacini ^a   Levy Neto, Maurício ^a   Aikawa, Nádia Emi ^a   de Medeiros Ribeiro, Ana Cristina ^a   Schahin Saad, Carla Gonçalves ^a   Precioso, Alexander ^a   Silva, Clovis Artur ^a   Bonfá, Eloisa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Autoantibody; Dermatomyositis; Polymyositis; Seroconversion; Vaccination

Indexed keywords

CREATINE KINASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE;

ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DRUG SAFETY; ENZYME ANALYSIS; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; OUTCOME ASSESSMENT; POLYMYOSITIS; PRIORITY JOURNAL; SEROCONVERSION; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ADULT; AUTOANTIBODIES; DERMATOMYOSITIS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; POLYMYOSITIS;

EID: 84870480419     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.063     Document Type: Article

References (26)

1. Centers for Disease Control Prevention (CDC) Update: novel influenza A (H1N1) virus infections-worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep 2009, 58:453-458.
2. Jain R., Goldman R.D. Novel influenza A (H1N1): clinical presentation, diagnosis, and management. Pediatr Emerg Care 2009, 25:791-796.
3. Centers for Disease Control Prevention (CDC) Deaths and hospitalizations related to 2009 pandemic influenza A (H1N1): Greece, May 2009-February 2010. MMWR Morb Mortal Wkly Rep 2010, 59:682-686.
4. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
5. van Assen S., Agmon-Levin N., Elkayam O., Cervera R., Doran M.F., Dougados M., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70:414-422.
6. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010, 59:1-62.
7. Elkayam O., Bashkin A., Mandelboim M., Litinsky I., Comaheshter D., Levartovsky D., et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010, 39:442-527.
8. Gabay C., Bel M., Combescure C., Ribi C., Meier S., Posfay-Barbe K., et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011, 63:1486-1496.
9. Ogimi C., Tanaka R., Saitoh A., Oh-Ishi T. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J 2011, 30:208-211.
10. Orbach H., Tanay A. Vaccines as a trigger for myopathies. Lupus 2009, 18:1213-1216.
11. Jani F.M., Gray J.P., Lanham J. Influenza vaccine and dermatomyositis. Vaccine 1994, 12:1484.
12. Winkelmann R.K. Influenza vaccine and dermatomyositis. Lancet 1982, 28(2):495.
13. Altman A., Szyper-Kravitz M., Shoenfeld Y. HBV vaccine and dermatomyositis: is there an association. Rheumatol Int 2008, 28:609-612.
14. Saad C.G.S., Borba E.F., Aikawa N.E., Silva C.A., Pereira R.M., Calich A.L., et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011, 70:1068-1073.
15. Bohan A., Peter J.B. Polymyositis and dermatomyositis. N Engl J Med 1975, 13:344-347.
16. Centers for Disease Control Prevention (CDC) Update: influenza activity - United States, 2010-11 season, and composition of the 2011-12 influenza vaccine. MMWR Morb Mortal Wkly Rep 2011, 60:705-712.
17. Miller F.W., Rider G.L., Chung Y.L., Cooper R., Danko K., Farewell V., et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001, 40:1262-1273.
18. Rider L.G., Feldman B.M., Perez M.D., Rennebohm R.M., Lindsley C.B., Zemel L.S., et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Arthritis Rheum 1997, 40:1976-1983.
19. Rider L.G., Giannini E.H., Harris-Love M., Joe G., Isenberg D., Pilkington C., et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003, 30:603-617.
20. Cook I.F. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008, 26:3551-3555.
21. Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009, 18:1217-1225.
22. Shoenfeld Y., Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36:4-8.
23. Katzav A., Kivity S., Blank M., Shoenfeld Y., Chapman J. Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus 2012, 21:210-216.
24. Aikawa N.E., Campos L.M., Silva C.A., Carvalho J.F., Saad C.G., Trudes G., et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol 2012, 39:167-173.
25. Borba E.F., Saad C.G., Pasoto S.G., Calich A.L., Aikawa N.E., Ribeiro A.C., et al. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?. Rheumatology (Oxford) 2012, 51:1061-1069.
26. Ribeiro A.C.M., Guedes L.K.N., Moraes J.C.B., Saad C.G., Aikawa N.E., Calich A.L., et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis 2011, 70:2144-2147.